Iris Grossman
Chief Therapeutics Officer Eleven Therapeutics
Seminars
Thursday 16th July 2026
Roundtable Discussion: The Maintenance Inflection Point: Transitioning from Clinical-Procedure Injections to Daily Prescriptive Habits for LifeLong Stability
2:40 pm
- Synthesizing “injectable-strength” efficacy in oral formats to challenge the historical potency gap, evaluating how synthetic small-molecule platforms are bypassing gastric proteolytic barriers to achieve double-digit weight loss without the strict fasting requirements or the bioavailability limitations of traditional oral peptides
- Assessing the “persistence-pivot” from induction to maintenance, examining realworld adherence data to determine if the convenience of a needle-free daily pill can overcome the 90-day discontinuation risk prevalent in long-term injectable therapy, effectively securing a stable market share in the chronic management phase
- Strategizing for global scalability and payer alignment by leveraging the cost and distribution advantages of synthetic manufacturing to bypass the “cold-chain” bottleneck, ensuring that the next wave of metabolic innovation can meet the 85 million-patient demand while providing the robust evidence required for universal insurance coverage
